GlassScriptPhysician profile
Dylan Michael Usenick
NPI 1134998321
$916.29
in general payments reported to CMS, 2019-2025
15 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $121 · 2024: $493 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.27 | 2024-2025 | |
| Novo Nordisk INC | $193.41 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $90.00 | 2024-2025 | Breztri |
| Pfizer INC. | $67.63 | 2024-2025 | |
| Exact Sciences Corporation | $59.23 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $53.10 | 2025 | Auvelity |
| Dexcom, INC. | $50.65 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $45.14 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.61 | 2025 | Caplyta |
| Lilly USA, LLC | $28.99 | 2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $21.15 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $21.06 | 2025 | Vaqta, Gardasil 9, Vaxelis |
| Astellas Pharma US INC | $20.74 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $17.69 | 2024 | Gvoke Hypopen |
| Cipher Pharmaceuticals US LLC | $15.62 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Usenick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.